Z-octadeca-9,12-dienoic acid methylamide | 3140-44-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Z-octadeca-9,12-dienoic acid methylamide
• 英文别名: N-Methyllinolamid；(9Z,12Z)-N-methyloctadeca-9,12-dienamide
• CAS: 3140-44-1
• 化学式: C₁₉H₃₅NO
• 分子量: 293.493
• InChiKey: RIVXWVPBUIBABF-NQLNTKRDSA-N

物化性质

• 沸点：
  443.6±24.0 °C(Predicted)
• 密度：
  0.875±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  21
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Z-octadeca-9,12-dienoic acid methylamide 在 lead(IV) acetate 、 lithium chloride 作用下， 生成 2-Chloro-octadecanoic acid methylamide
  参考文献：
  名称：

  金属化反应。第十部分。酰胺基存在下的烯丙基金属化：长距离相互作用

  摘要：

  亚油酸的N-甲基酰胺通过丁基锂在醚或己烷α中金属化成酰胺基团和/或在双烯丙基位置，而不加羰基。产物的比例取决于溶剂。的Metallations NN也得到二甲基linoleamine。这些锂衍生物的碳酸化位置揭示了官能团的长期作用。为了比较，制备了在链的各个位置具有一个另外的羧基的一系列十八烷酸。在酰胺的四甲基乙二胺具有共轭的两个双键的存在下的金属化产物将丁基锂加成到二烯上。

  DOI：

  10.1039/j39710003821
• 作为产物：
  描述：

  (Z,Z)-9,12-十八烷二烯酸二聚物 在 氯化亚砜 作用下， 以 N,N-二甲基甲酰胺 、 苯 为溶剂， 反应 13.92h， 生成 Z-octadeca-9,12-dienoic acid methylamide
  参考文献：
  名称：

  Synthesis, characterization and corrosion inhibition studies of polyunsaturated fatty acid derivatives on the acidic corrosion of mild steel: Experimental and computational studies

  摘要：

  In an effort to make an efficient and benign a for the purpose of acidizing, a novel range of new derivatives of polyunsaturated fatty acids (PUFA) were prepared from a group of amines and Z-9,12-octadecadienoic add with Excellent yields. Elemental analysis, FTIR, C-13 NMR and H-1 NMR was employed to realize a description for the newly manufactured compound. The inhibitive action of synthesized amides was examined by means of potentiodynamic polarization techniques and weight loss measurements in 1.00 M HCl. Derivatives of Z-9,12-octadecadienoic add amides (DA) were found to obey the Langmuir adsorption model The hydrophobic nature of mild steel (MS) was revealed by measurement of the contact angle in the presence of Cl. The experimental findings were found to be supported by quantum chemical calculations. Inhibition efficiencies were computed for various DA concentrations for inhibition against the wear of MS in 100.00 ml of 1.00 M Ha, with exposure for four days at temperatures ranging from 298 to 333 K. For a DA concentration of 100 ppm, every inhibitor molecule showed outstanding percentage inhibition efficiencies in 1.00 M HCl. Compounds 2, 3,4, 5, 6, 7, 8 and 9 offered a robust percentage inhibition efficiency of 92.90, 86.6, 49.8, 82.7, 85.9, 96.70, 9430 and 9130, correspondingly, at 100 ppm The interaction of the p-electrons in compounds with low-energy, empty Fe d-orbitals helped the inhibitive molecules (IMs) to experience adsorption and inhibit the process of anodic dissolution. When Tafel plots were employed for the compounds used in the electrochemical method, similar findings were obtained for the percentage inhibition efficiencies. Compound adsorption on the MS surface was discovered to obey Arrhenius and Transition state plots in 1.00 M HCl. (C) 2020 Elsevier LW. All rights reserved.

  DOI：

  10.1016/j.molliq.2020.114162

文献信息

• NEW USES OF LIPOPHENOLIC COMPOUNDS
  申请人：UNIVERSITE DE MONTPELLIER

  公开号：EP3482758A1

  公开（公告）日：2019-05-15

  The present invention relates to compound of formula (I) : wherein R is O-R3 or R1 and R2 are identical or different and are each independently H, (C1-C6)alkyl, -CO-(C1-C21)alkyl or -CO-(C11-C21)alkenyl group, provided that at least one of R1 or R2 is H or (C1-C6)alkyl, R3 is a -CO-(C11-C21)alkyl or -CO-(C11-C21)alkenyl group, or its pharmaceutically acceptable salts, racemates, diastereoisomers, enantiomers, or mixtures thereof, for use in prevention and/or treatment of a disease or disorder linked to an exacerbated vascular, lymphatic or mucosal permeability.

  本发明涉及以下式的化合物（I）：其中R为O-R3或R1和R2相同或不同且各自独立为H，（C1-C6）烷基，-CO-(C1-C21)烷基或-CO-(C11-C21)烯基，但至少R1或R2中的一个为H或（C1-C6）烷基，R3为-CO-(C11-C21)烷基或-CO-(C11-C21)烯基，或其药学上可接受的盐、拉克酸盐、二对映异构体、对映体或其混合物，用于预防和/或治疗与加剧的血管、淋巴或黏膜通透性相关的疾病或疾患。
• COMPLEX OF NUCLEIC ACID MEDICINE AND MULTIBRANCHED LIPID
  申请人：Shionogi & Co., Ltd

  公开号：EP3603648A1

  公开（公告）日：2020-02-05

  The purpose of the present invention is to provide novel complexes that improve the effect of nucleic acid medicines. Provided is a complex in which a multibranched lipid(s) binds through a linker to a strand of an oligonucleotide comprising a nucleic acid medicine having suppressing activity of the target gene expression.

  本发明的目的是提供可改善核酸药物效果的新型复合物。 本发明提供了一种复合物，在该复合物中，多支链脂质通过连接体与包含具有抑制靶基因表达活性的核酸药物的寡核苷酸链结合。
• Epoxidation of carbon-carbon double bond with membrane bound peroxygenase
  申请人：——

  公开号：US20030040090A1

  公开（公告）日：2003-02-27

  A method has been discovered for the epoxidation of a compound having at least one carbon-carbon double bond, the method involves reacting a compound having at least one carbon-carbon double bond, a solvent, an oxidant, and membrane bound peroxygenase. Also discovered is a method for preparing the membrane bound peroxygenase involving grinding seeds containing peroxygenase to produce ground seeds, homogenizing the ground seeds in a buffer to form a slurry, centrifuging the slurry to produce a first supernatant, centrifuging the first supernatant to produce a second supernatant, and filtering said second supernatant through a protein-binding membrane filter to produce membrane bound peroxygenase; optionally the second supernatant is filtered through a hydrophilic membrane filter prior to filtering the second supernatant through a protein-binding membrane filter.

  发现了一种使具有至少一个碳碳双键的化合物发生环氧化反应的方法，该方法包括使具有至少一个碳碳双键的化合物、溶剂、氧化剂和膜结合过氧酶发生反应。还发现了一种制备膜结合过氧化氢酶的方法，包括研磨含有过氧化氢酶的种子以产生磨碎的种子，在缓冲液中均质磨碎的种子以形成浆液，离心浆液以产生第一上清液，离心第一上清液以产生第二上清液，通过蛋白质结合膜过滤器过滤所述第二上清液以产生膜结合过氧化氢酶；在通过蛋白质结合膜过滤器过滤第二上清液之前，可选择通过亲水膜过滤器过滤第二上清液。
• A METHOD FOR TREATING PERIPHERAL INFLAMMATORY DISEASE
  申请人：Dublin City University

  公开号：EP3297621A1

  公开（公告）日：2018-03-28
• AMINE CATIONIC LIPIDS AND USES THEREOF
  申请人：Dicerna Pharmaceuticals, Inc.

  公开号：EP3597644B1

  公开（公告）日：2021-09-29